Clinical Trial Update: Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

A multicenter, open-label Phase III study randomizes tislelizumab plus FOLFOX versus POF in locally advanced or metastatic gastric and gastroesophageal junction…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• PACLITAXEL (PACLITAXEL)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Gastric Cancer | Phase 3 | Status: RECRUITING